Shield Therapeutics plc (LON:STX – Get Free Report) shares rose 11.5% during mid-day trading on Friday . The stock traded as high as GBX 4.80 ($0.06) and last traded at GBX 4.79 ($0.06). Approximately 1,228,729 shares changed hands during trading, a decline of 75% from the average daily volume of 4,819,253 shares. The stock had previously closed at GBX 4.30 ($0.06).
Shield Therapeutics Stock Up 11.5 %
The firm has a market cap of £37.48 million, a P/E ratio of -106.05 and a beta of 1.42. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The firm has a fifty day moving average of GBX 4.11 and a 200-day moving average of GBX 2.61.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More
- Five stocks we like better than Shield Therapeutics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- The Most Important Warren Buffett Stock for Investors: His Own
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- How to Buy Cheap Stocks Step by Step
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
